Evidence map›Paper›PMID 34929590›Full record

ArticleVirology2022

Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Bo Ryoung Park, Jeeva Subbiah, Ki-Hye Kim, Young-Man Kwon, Judy Oh, Min-Chul Kim, Chong-Hyun Shin, Baik Lin Seong, Sang-Moo Kang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Bo Ryoung ParkInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Jeeva SubbiahInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Ki-Hye KimInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Young-Man KwonInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Judy OhInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Min-Chul KimInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA; CARESIDE Co., Ltd., Seongnam, Gyeonggi-do, Republic of Korea.
Chong-Hyun ShinInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.
Baik Lin SeongDepartment of Microbiology, College of Medicine, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea; Vaccine Innovative Technology ALliance (VITAL)-Korea, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Sang-Moo KangInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA. Electronic address: skang24@gsu.edu.
Georgia State University · USYonsei University · KR

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
Seasonal and universal Vaccination in aged populations with pre-existing immunityR01AI154656 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2021 to 2025
$2.7M
Universal epitopes-based recombinant influenza vaccinesR21AI147042 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2020 to 2021
$428k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI154656NIAID NIH HHS R21 AI147042
6 · The paper itself

Abstract

Annual repeat influenza vaccination raises concerns about protective efficacy against mismatched viruses. We investigated the impact of heterologous prime-boost vaccination on inducing cross protection by designing recombinant influenza viruses with chimeric hemagglutinin (HA) carrying M2 extracellular domains (M2e-HA). Heterologous prime-boost vaccination of C57BL/6 mice with M2e-HA chimeric virus more effectively induced M2e and HA stalk specific IgG antibodies correlating with cross protection than homologous prime-boost vaccination. Induction of M2e and HA stalk specific IgG antibodies was compromised in 1-year old mice, indicating significant aging effects on priming subdominant M2e and HA stalk IgG antibody responses. This study demonstrates that a heterologous prime-boost strategy with recombinant influenza virus expressing extra M2e epitopes provides more effective cross protection than homologous vaccination.

Indexed as

Age FactorsAgingAnimalsAntibodies, ViralAntigens, ViralCross ProtectionFemaleHemagglutinin Glycoproteins, Influenza VirusHumansImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesAntibodies, ViralAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GInfluenza VaccinesM1 protein, Influenza A virusRecombinant Fusion ProteinsVaccines, SyntheticViral Matrix ProteinsCross protectionLive attenuated virusM2eRecombinant influenza virus

Identifiers

PMID34929590
PMCPMC8903020
OpenAlexW4200079410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.